-
公开(公告)号：EP3087095B1
公开(公告)日：2019-08-07
申请号：EP14827372.5
申请日：2014-12-23
-
公开(公告)号：EP3626738A1
公开(公告)日：2020-03-25
申请号：EP19189186.0
申请日：2014-12-23
发明人： ULRICHTS, Peter , BLANCHETOT, Christophe , DREIER, Torsten , DE HAARD, Johannes , WARD OBER, E., Sally , ONGENAE, Nicolas G.H.
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
-
公开(公告)号：EP3087095A1
公开(公告)日：2016-11-02
申请号：EP14827372.5
申请日：2014-12-23
发明人： ULRICHTS, Peter , BLANCHETOT, Christophe , DREIER, Torsten , DE HAARD, Johannes , WARD OBER, E. Sally , ONGENAE, Nicolas G.H.
CPC分类号： C07K14/4703 , A61K38/00 , A61K38/1709 , A61K45/06 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/94
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
摘要翻译： 提供了新的FcRn拮抗剂组合物，其包含与FcRn特异性结合的变体Fc区，其具有增加的亲和力并降低相对于天然Fc区的pH依赖性。 还提供了具有增强的CD16结合亲和力的FcRn拮抗剂。 还提供了使用这些FcRn拮抗剂组合物治疗抗体介导的病症（例如自身免疫疾病）的方法，编码FcRn拮抗剂组合物的核酸，用于制备FcRn拮抗剂组合物的重组表达载体和宿主细胞，以及包含FcRn拮抗剂的药物组合物 成分。
-
公开(公告)号：EP3625249A1
公开(公告)日：2020-03-25
申请号：EP18725795.1
申请日：2018-05-10
申请人： Argenx BVBA
IPC分类号： C07K16/00
-
5.发明公开METHODS OF REDUCING SERUM LEVELS OF FC-CONTAINING AGENTS USING FCRN ANTAGONSITS 审中-公开使用FCRN抗体降低含FC剂的血清水平的方法
公开(公告)号：EP3268391A1
公开(公告)日：2018-01-17
申请号：EP16719896.9
申请日：2016-03-08
申请人： argenx BVBA
发明人： ONGENAE, Nicolas, G.h. , DREIER, Torsten , ULRICHTS, Peter , DE HAARD, Johannes , BLANCHETOT, Christophe
CPC分类号： C07K16/283 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/00 , C07K16/2875 , C07K16/2887 , C07K16/40 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/732 , C07K2317/76
摘要： Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).
-
公开(公告)号：EP4006051A1
公开(公告)日：2022-06-01
申请号：EP21189336.7
申请日：2016-03-08
申请人： Argenx BVBA
发明人： ONGENAE, Nicolas, G.h , DREIER, Torsten , ULRICHTS, Peter , DE HAARD, Johannes , BLANCHETOT, Christophe
IPC分类号： C07K16/00 , A61K38/17 , A61K45/06 , C07K16/28 , C07K16/40 , C07K14/47 , A61K39/00 , A61P21/04 , A61P25/00 , A61P25/08 , A61P43/00 , A61P7/00 , A61P37/06
摘要： Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.015 秒)
